Showing results (1-10 of 137) with videos related to
Sort By:
Pageof 14
Current Opinion in HIV and AIDS|April 18, 2009
Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyondTomas CihlarCurrent Opinion in Virology|March 30, 2016
Current status and prospects of HIV treatmentTomas Cihlar, Marshall FordyceAntiviral Research|December 19, 2009
Current status and challenges of antiretroviral research and therapyJosé A Esté, Tomas CihlarAntiviral Therapy|May 2, 2022
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19Tomas Cihlar, Richard L MackmanAntiviral Research|November 6, 2009
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudineTomas Cihlar, Adrian S RayAntiviral Therapy|April 5, 2014
Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicityRujuta A Bam, Stephen R Yant, Tomas CihlarAntimicrobial Agents and Chemotherapy|February 19, 2002
Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitorsGabriel Birkus, Michael J M Hitchcock, Tomas CihlarAnnual Review of Pharmacology and Toxicology|August 3, 2016
Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a ModelMaaike Everts, Tomas Cihlar, J Robert Bostwick, et al.Antiviral Research|March 13, 2002
Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitorsTomas Cihlar, Gabriel Birkus, Dale E Greenwalt, et al.Journal of the American Society of Nephrology : JASN|March 7, 2000
Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1Edmund S Ho, Deborah C Lin, Dirk B Mendel, et al.Pageof 14